Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04434040
Title Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

triple-receptor negative breast cancer

Therapies

Atezolizumab + Ipatasertib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of California San Francisco Recruiting San Francisco California 94115 United States Details
University of Chicago Medical Center Recruiting Chicago Illinois 60637 United States Details
University of Chicago Comprehensive Cancer Center at Silver Cross Hospital Recruiting New Lenox Illinois 60451 United States Details
University of Chicago Medical Center for Advanced Care Orland Park Recruiting Orland Park Illinois 60462 United States Details
Massachusetts General Hospital Not yet recruiting Boston Massachusetts 02114 United States Details
Beth Israel Deaconess Medical Center Not yet recruiting Boston Massachusetts 02215 United States Details
Dana-Farber Cancer Institute Recruiting Boston Massachusetts 02215 United States Details
University of Pennsylvania-Abramson Cancer Center Recruiting Philadelphia Pennsylvania 19104 United States Details
Vanderbilt-Ingram Cancer Center Recruiting Nashville Tennessee 37232 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field